Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.77 |
| ▸ | CA1 | P00915 | 4/20 | 0.77 |
| ▸ | CA2 | P00918 | 4/20 | 0.77 |
| ▸ | CA7 | P43166 | 4/20 | 0.77 |
| ▸ | CA9 | Q16790 | 4/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.77 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070351 | 0.88 | CA12 (0.61) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1519936 | 0.88 | CA12 (1.00) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28869955 | 0.85 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8479501 | 0.84 | CA1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30632216 | 0.81 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30432593 | 0.81 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL621753 | 0.81 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8056782 | 0.81 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20899341 | 0.80 | CA12 (0.79) | CA12CA1CA2CA7CA9 | |
| SCHEMBL17374999 | 0.80 | CA12 (0.48) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118904215-A | Polymerization system and polymerization method of 2-hydroxy-6-fluorobenzoic acid methyl ester | 江苏万隆化学有限公司 | 2024-11-08 | — | — | CN | claimed |
| US-20240115470-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | SA, GIVAUDAN (CH) | 2024-04-11 | — | — | US | claimed |
| CN-117796401-A | Preparation process of 2-hydroxy-6-fluorobenzoic acid methyl ester-containing intermediate antibacterial agent | 江苏万隆化学有限公司 | 2024-04-02 | — | — | CN | claimed |
| EP-4259082-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | Givaudan SA (CH) | 2023-10-18 | — | — | EP | claimed |
| WO-2022122836-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | GIVAUDAN SA (CH) | 2022-06-16 | — | — | WO | claimed |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | Vettore, LLC | 2026-02-26 | — | — | US | disclosed |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| WO-2025061035-A1 | BRM SELECTIVE DEGRADATION AGENT COMPOUND AND USE THEREOF | 南京再明医药有限公司 | 2025-03-27 | — | — | WO | disclosed |
| CN-118904215-A | Polymerization system and polymerization method of 2-hydroxy-6-fluorobenzoic acid methyl ester | 江苏万隆化学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118904215-A | Polymerization system and polymerization method of 2-hydroxy-6-fluorobenzoic acid methyl ester | 江苏万隆化学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118904215-A | Polymerization system and polymerization method of 2-hydroxy-6-fluorobenzoic acid methyl ester | 江苏万隆化学有限公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2005066143-A2 | BENZO[D]ISOXAZOL-3-OL DAAO INHIBITORS | SEPRACOR INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | SEPRACOR INC. (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005010006-A1 | SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-02-03 | — | — | WO | disclosed |
| US-20040209932-A1 | 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
| EP-0249708-B1 | 2-PHENOXYPYRIMIDINE DERIVATIVE AND HERBICIDAL COMPOSITIONS | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4985066-A | 2-phenoxypyrimidine derivative and herbicidal composition | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| US-4900352-A | 2-Phenoxypyimidine derivative and herbicidal composition | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1990-02-13 | — | — | US | disclosed |
| EP-0249708-A1 | 2-Phenoxypyrimidine derivative and herbicidal compositions | KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) | 1987-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143434-A1 | Benzo[d]isoxazol-3-ol DAAO inhibitors | DDO, DAO, CACNA1S | CA12 981/4885CA1 25/4885CA2 110/4885 |
| US-20040209932-A1 | 1,3-substitued cycloalkyl derivatives having acidic, mostly heterocyclic groups; processes for their preparation and their use as pharmaceuticals | GPR119, PC, CPT1A | CA12 3030/4885CA1 3407/4885CA2 1587/4885 |
| US-20240115470-A1 | METHYL-FLUORO-HYDROXYBENZOATES IN CONSUMER PRODUCTS | KDM5B, FOSB, KDM2B | CA12 2279/4885CA1 3577/4885CA2 2648/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | CA12 3436/4885CA1 2863/4885CA2 304/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | CA12 4808/4885CA1 4853/4885CA2 4637/4885 |
| US-20260055062-A1 | HETEROCYCLIC INHIBITORS OF MCT4 | SLC16A1, SLC16A3, SLC16A7 | CA12 3279/4885CA1 3982/4885CA2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.